Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
2017 ◽
Vol 18
(14)
◽
pp. 1433-1438
◽
Keyword(s):
Keyword(s):
2017 ◽
Vol 56
(6)
◽
pp. 597-604
◽
Keyword(s):
Keyword(s):
2011 ◽
Vol 94
(3)
◽
pp. 468-470
◽
Keyword(s):
2016 ◽
Vol 31
(6)
◽
pp. 924
◽
Keyword(s):
2015 ◽
Vol 109
(1)
◽
pp. 199-205
◽
Keyword(s):